Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.

Launched by HAMILTON HEALTH SCIENCES CORPORATION · Jun 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment approach for people with a type of liver cancer called hepatocellular carcinoma (HCC) that can be removed with surgery. The trial is comparing two groups: one group will receive radiation therapy followed by surgery, and the other group will receive radiation therapy combined with two medicines called durvalumab and tremelimumab before surgery. The goal is to see if the combination treatment helps the body’s immune system better attack the cancer and improve the condition of the tumor before surgery.

People who might be eligible for this study are adults with a single liver tumor that hasn’t spread to other parts of the body and who are healthy enough for surgery. Tumors need to be less than 12 centimeters in size, and participants should have good liver function and overall health. During the study, participants will receive treatments before surgery, and doctors will take samples of the tumor to see how it responds. This trial is designed to gather information quickly and safely, focusing on patients who are well enough to handle the treatments. If you or a loved one fit these criteria and are interested, a healthcare provider can help determine if this trial is a good option.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Radiologically or biopsy proven solitary HCC without biliary invasion or metastases, Liver Imaging Reporting and Data Systems (LI- RADS) 4 or 5 only. Participants with satellite tumour nodules are eligible. Satellitosis or a satellite nodule is defined as a tumour (LI-RADS 4 or 5 only) less than or equal to 2 cm and located less than or equal to 2 cm from the main tumour.
• • Tumour less than 12 cm in maximum size on CT or MRI.
• • Planned surgical resection of HCC with a life expectancy of at least 12 weeks
• • Age \>18 years at time of study entry.
• • Child-Pugh Class A within 14 days prior to study enrollment
• • Eastern Cooperative Oncology Group (ECOG) of 0 or 1 (see Appendix 3)
• • Body weight \>30 kg at time of study enrollment
• Adequate normal organ and marrow function as defined below:
• • Haemoglobin ≥9.0 g/dL
• • Absolute neutrophil count (ANC ≥1.0 × 109 /L)
• • Platelet count ≥75 × 109/L
• • Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN).
• • AST (SGOT)/ALT (SGPT) ≤2.5 x institutional upper limit of normal
• Measured creatinine clearance (CL) \>40 mL/min or Calculated creatinine clearance CL\>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance:
• Males:
• • Creatinine CL (mL/min) = Weight (kg) x (140 - Age)72 x serum creatinine (mg/dL)
• Females:
• • Creatinine CL (mL/min) = Weight (kg) x (140 - Age) x 0.85 72 x serum creatinine (mg/dL)
• • Patient is capable and willing to provide signed informed consent.
• Exclusion Criteria:
• • Previous therapy for HCC, including systemic therapy, surgery, radiation therapy, ablation or embolization.
• • Participation in another clinical study with an investigational product during the last 4 weeks or concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.
• • Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.
• • Previous radiation therapy or surgery within 4 weeks of the randomization.
• • Previous allogenic organ transplantation
• • Previous anti-PD-1, anti-PD-L1 or anti-CTLA-4 therapy
• • Previous receipt of durvalumab and / or tremelimumab or allergy to it
• • Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy except for alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
• • Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
• • Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study Physician.
• Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \[e.g., colitis or Crohn's disease\], diverticulitis \[with the exception of diverticulosis\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc.\]). The following are exceptions to this criterion:
• • Patients with vitiligo or alopecia
• • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
• • Any chronic skin condition that does not require systemic therapy
• • Patients without active disease in the last 5 years may be included but only after consultation with the study physician
• • Patients with celiac disease controlled by diet alone
• • History of active primary immunodeficiency
• • Conditions that would preclude administration of durvalumab and / or tremelimumab
• • Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent
• • Known active hepatitis infection, positive hepatitis C virus (HCV) antibody, hepatitis B virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Patients with a past or resolved HBV infection (defined as the presence of antiHBc and absence of HBsAg) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
• • b.1. Patients co-infected with HBV and HCV or co-infected with HBV and HDV, namely: HBV positive (presence of HBsAg and/or anti HBcAb with detectable HBV DNA); and
• • b.2. HCV positive (presence of anti-HCV antibodies); or
• • b.3. HDV positive (presence of anti-HDV antibodies)
• • b.4. Patients with HBV infection, characterized by positive HBsAg and/or anti-HBcAb with undetectable HBV DNA (\< 10 IU/ml or under the limit of detection per local lab standard) do not require antiviral therapy prior to enrollment. These patients will be tested once for HBV DNA levels; if HBV DNA is detected (≥ 10 IU/ml or above the limit of detection per local lab standard), antiviral therapy must be initiated, continued for the study duration and for 6 months after the last dose of IP.
• • Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) which is not well controlled or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
• • c.1. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA load for 3 months, CD4+ count of \>200 no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 3 months on the same anti-HIV medications.
• • History of another primary malignancy, except for
• • Malignancy treated with curative intent and with no known active disease ≥2 years before randomization and of low potential risk for recurrence
• • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
• • Adequately treated carcinoma in situ without evidence of disease
• Current or prior use of immunosuppressive medication within 14 days before enrollment. The following are exceptions to this criterion:
• • Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)
• • Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
• • Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)
• • Receipt of live attenuated vaccine within 30 days prior to enrollment. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 90 days after the last dose of IP.
• • Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab and tremelimumab combination therapy.